Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Feb 12;70(3):261-72.
doi: 10.2165/11532180-000000000-00000.

Rituximab for the Treatment of non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia

Affiliations
Review

Rituximab for the Treatment of non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukaemia

Fredrick Hagemeister. Drugs. .

Abstract

Rituximab is a monoclonal antibody that is widely utilized in the treatment of a number of B-cell-derived haematological malignancies. Rituximab, in combination with chemotherapy, has significantly improved survival outcomes for patients diagnosed with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), the two most commonly diagnosed subtypes of non-Hodgkin's lymphoma. Furthermore, chemoimmunotherapy containing rituximab has led to significant increases in complete response and progression-free survival rates for patients with both previously untreated and relapsed or refractory chronic lymphocytic leukaemia (CLL). This article reviews the efficacy data from clinical trials demonstrating the significant survival benefits associated with rituximab use in the treatment of FL, DLBCL and CLL.

Similar articles

See all similar articles

Cited by 16 articles

See all "Cited by" articles

References

    1. Cancer Immunol Immunother. 2000 Mar;48(12):673-83 - PubMed
    1. Sci STKE. 2004 Jul 06;2004(241):pe30 - PubMed
    1. Blood. 2008 Aug 15;112(4):975-80 - PubMed
    1. J Clin Oncol. 2001 Apr 15;19(8):2153-64 - PubMed
    1. Blood. 1999 Feb 1;93(3):1032-7 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback